Aethlon Medical Reports Board and Officer Changes
Ticker: AEMD · Form: 8-K · Filed: Oct 3, 2024 · CIK: 882291
| Field | Detail |
|---|---|
| Company | Aethlon Medical Inc (AEMD) |
| Form Type | 8-K |
| Filed Date | Oct 3, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
TL;DR
Aethlon Medical shakes up its board and exec team, new comp plans in play.
AI Summary
Aethlon Medical, Inc. filed an 8-K on October 3, 2024, reporting changes in its board of directors and executive officers. The filing details the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for key personnel.
Why It Matters
Changes in a company's leadership and compensation structures can signal shifts in strategic direction or operational focus, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in executive and board composition can introduce uncertainty regarding future strategy and operational stability.
Key Players & Entities
- Aethlon Medical, Inc. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- 11555 Sorrento Valley Road, Suite 203 (address) — Principal executive offices
- San Diego, California (location) — City and State of principal executive offices
- October 3, 2024 (date) — Date of earliest event reported
FAQ
What specific roles have seen departures or appointments?
The filing indicates the departure of certain officers and the election of new directors, though specific names and roles are not detailed in the provided excerpt.
When was the earliest event reported in this 8-K?
The earliest event reported in this 8-K was on October 3, 2024.
What is Aethlon Medical's state of incorporation?
Aethlon Medical, Inc. is incorporated in Nevada.
Where are Aethlon Medical's principal executive offices located?
Aethlon Medical's principal executive offices are located at 11555 Sorrento Valley Road, Suite 203, San Diego, California.
What type of SEC filing is this?
This is a Form 8-K, a Current Report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 818 words · 3 min read · ~3 pages · Grade level 10.6 · Accepted 2024-10-03 16:44:19
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share AEMD The Nasdaq
Filing Documents
- aethlon_8k.htm (8-K) — 28KB
- 0001683168-24-006896.txt ( ) — 200KB
- aemd-20241003.xsd (EX-101.SCH) — 3KB
- aemd-20241003_lab.xml (EX-101.LAB) — 33KB
- aemd-20241003_pre.xml (EX-101.PRE) — 24KB
- aethlon_8k_htm.xml (XML) — 4KB
02 Departure of Directors or Certain
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of James B. Frakes as Permanent Chief Executive Officer Effective October 3, 2024, the board of directors (the "Board") of Aethlon Medical, Inc. (the "Company") appointed James B. Frakes to serve as the Company's permanent Chief Executive Officer. He has been serving as Interim Chief Executive Officer since November 7, 2023. Mr. Frakes will also continue his role as Chief Financial Officer of the Company and as member of the Board. Mr. Frakes has served as Interim Chief Executive Officer and as a director of the Company since November 2023, and has served as Chief Financial Officer of the Company since September 2010. Prior to being appointed as Chief Financial Officer, Mr. Frakes served as Senior Vice President, Finance of the Company from January 2008 to September 2010. He previously served as the Chief Financial Officer for Left Behind Games Inc., a start-up video game company. Prior to 2006, he served as Chief Financial Officer of NTN Buzztime, Inc., an interactive entertainment company. Mr. Frakes received an MBA from the University of Southern California and a B.A. with Honors from Stanford University. In connection with Mr. Frakes' appointment as the Company's permanent Chief Executive Officer, the Company intends to enter into an amended executive employment agreement with Mr. Frakes to modify certain terms of his current agreement. There is no arrangement or understanding between Mr. Frakes and any other person pursuant to which Mr. Frakes was appointed as the permanent Chief Executive Officer of the Company. There are no family relationships between Mr. Frakes and any of the Company's directors, executive officers or persons nominated or chosen by the Company to become a director or executive officer. Mr. Frakes has not engaged in any related-person transactions required to be disclo
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 3, 2024 Aethlon Medical, Inc. By: /s/ James B. Frakes Name: James B. Frakes Chief Executive Officer and Chief Financial Officer 3